Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (262) Arrow Down
Filter Results: (262) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (262)
    • News  (29)
    • Research  (197)
    • Multimedia  (2)
  • Faculty Publications  (103)

Show Results For

  • All HBS Web  (262)
    • News  (29)
    • Research  (197)
    • Multimedia  (2)
  • Faculty Publications  (103)
← Page 4 of 262 Results →

    Stephen P. Bradley

    Professor Bradley is the William Ziegler Professor of Business Administration Emeritus at the Harvard Business School. In addition to teaching Management and Strategy in the Owner President Management Program and leading an... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
    • October 2004 (Revised July 2010)
    • Case

    Product Team Cialis: Getting Ready to Market

    By: Elie Ofek
    Lilly and ICOS are preparing for the launch of a new drug, Cialis, to compete against Viagra. To position against the incumbent firm Pfizer, which developed and markets Viagra, and other newcomers into the erectile dysfunction market, they must determine how best to... View Details
    Keywords: Communication Strategy; Marketing Strategy; Product Launch; Product Positioning; Competition; Competitive Advantage; Segmentation; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Ofek, Elie. "Product Team Cialis: Getting Ready to Market." Harvard Business School Case 505-038, October 2004. (Revised July 2010.)
    • 20 Nov 2007
    • First Look

    First Look: November 20, 2007

    a period of financial repression. Nationalization led to lower interest rates and lower quality intermediation and may have slowed employment gains in trade and services. Development lending goals were met, but these had no real impact. Finally, View Details
    Keywords: Martha Lagace
    • February 2001 (Revised July 2006)
    • Case

    Discovering the Future: R&D Strategy at Merck

    By: Gary P. Pisano
    Given explosive growth in technologies for drug discovery, how does Merck remain competitive in an industry that is fragmented and continues to consolidate? View Details
    Keywords: Competitive Strategy; Research and Development; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Pisano, Gary P. "Discovering the Future: R&D Strategy at Merck." Harvard Business School Case 601-086, February 2001. (Revised July 2006.)
    • September 2023 (Revised December 2023)
    • Case

    TetraScience: Noise and Signal

    By: Thomas R. Eisenmann and Tom Quinn
    In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from... View Details
    Keywords: Entrepreneurship; Business Growth and Maturation; Business Organization; Restructuring; Forecasting and Prediction; Digital Platforms; Analytics and Data Science; AI and Machine Learning; Organizational Structure; Network Effects; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States; Boston
    Citation
    Educators
    Purchase
    Related
    Eisenmann, Thomas R., and Tom Quinn. "TetraScience: Noise and Signal." Harvard Business School Case 824-024, September 2023. (Revised December 2023.)

      Elon Kohlberg

      Elon Kohlberg is the Royal Little Professor of Business Administration at the Harvard Business School. His research is mainly in Game Theory, in particular the study of non-cooperative equilibrium.

      Professor Kohlberg has taught many courses in the MBA,... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • 06 May 2008
      • First Look

      First Look: May 6, 2008

      company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a strategic perspective, the (A) case provides brief histories of the two companies; traces the global confectionery industry, focusing... View Details
      Keywords: Martha Lagace
      • 12 Feb 2008
      • First Look

      First Look: February 12, 2007

        Working PapersColonial Land Tenure, Electoral Competition and Public Goods in India Authors:Abhijit Banerjee and Lakshmi Iyer No abstract is available at this time. Download the paper: http://www.hbs.edu/research/pdf/08-062.pdf... View Details
      Keywords: Martha Lagace

        Nitin Nohria

        Nitin Nohria served as the tenth dean of Harvard Business School from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.

        As Dean, building on... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • 03 Apr 2007
        • First Look

        First Look: April 3, 2007

        different development strategies. The states had to decide whether to focus their investment efforts on physical capital or improving social indicators. Both states faced constraints in the form of budget deficits, competition from other... View Details
        Keywords: Martha Lagace

          Gary P. Pisano

          Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
          • 02 Aug 2011
          • First Look

          First Look: August 2

          pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
          Keywords: Sean Silverthorne
          • June 1999 (Revised June 2000)
          • Case

          Eckerd Corporation

          By: Michael E. Porter and John E. Kelleher
          Describes the history and current situation in the retail pharmacy industry, including competition from new merchants and Internet drugstores. Eckerd, one of the top four drug chains, must decide how to position itself for the future. View Details
          Keywords: Competition; Alignment; Supply and Industry; Pharmaceutical Industry; Pharmaceutical Industry
          Citation
          Educators
          Purchase
          Related
          Porter, Michael E., and John E. Kelleher. "Eckerd Corporation." Harvard Business School Case 799-141, June 1999. (Revised June 2000.)
          • October 2019
          • Case

          Impax Laboratories: Executing Accretive Acquisitions (A)

          By: Benjamin C. Esty and Daniel Fisher
          Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
          Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
          Citation
          Educators
          Purchase
          Related
          Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Acquisitions (A)." Harvard Business School Case 220-030, October 2019.
          • October 2019
          • Supplement

          Impax Laboratories: Executing Accretive Transactions (A)

          By: Benjamin C. Esty and Daniel Fisher
          Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
          Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
          Citation
          Purchase
          Related
          Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Transactions (A)." Harvard Business School Spreadsheet Supplement 220-710, October 2019.
          • 16 Jan 2018
          • First Look

          First Look at New Research and Ideas, January 16, 2018

          explores whether the strategy will save the Chinese economy or generate social and political problems that imperil the country's growth and stability. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=53716 Lone Wolves in View Details
          Keywords: Sean Silverthorne
          • Web

          Faculty & Advisors | MBA

          Crinetics Pharmaceuticals (NASDAQ: CRNX), among others. Earlier in her career Dr. Chang was a Project Leader at The Boston Consulting and a member of the Healthcare Practice. Dr. Chang trained clinically in internal medicine and... View Details
          • 11 Sep 2007
          • First Look

          First Look: September 11, 2007

          own profits when one side is subsidized in equilibrium. By contrast, if platforms make positive margins on both sides, the same investment has the regular, expected effects. Our analysis implies that the strategy space and the logic of View Details
          Keywords: Martha Lagace
          • Web

          Strategy - Doctoral

          Strategy The doctoral program in Strategy encourages students to pursue multi-disciplinary research that utilizes multiple methodologies—quantitative, as well as qualitative—to study how companies and industries around the world develop and sustain View Details
          • March 2002 (Revised May 2002)
          • Case

          Genzyme: Engineering the Market for Orphan Drugs

          Genzyme has made money with external technology in orphan drug markets generally considered to be too small to be attractive to other drug companies. Now competition is entering these same markets, placing Genzyme's business model under new pressures. View Details
          Keywords: Business Model; Information Technology; Market Entry and Exit; Pharmaceutical Industry; Pharmaceutical Industry
          Citation
          Educators
          Purchase
          Related
          Chesbrough, Henry W., and Clarissa Ceruti. "Genzyme: Engineering the Market for Orphan Drugs." Harvard Business School Case 602-147, March 2002. (Revised May 2002.)
          • ←
          • 4
          • 5
          • …
          • 13
          • 14
          • →
          ǁ
          Campus Map
          Harvard Business School
          Soldiers Field
          Boston, MA 02163
          →Map & Directions
          →More Contact Information
          • Make a Gift
          • Site Map
          • Jobs
          • Harvard University
          • Trademarks
          • Policies
          • Accessibility
          • Digital Accessibility
          Copyright © President & Fellows of Harvard College.